RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- Kinetigen, Inc., a specialty pharmaceutical consulting firm with global reach, is pleased to announce the addition of Mark Sale, MD to its experienced team of drug development professionals. Dr. Sale strengthens Kinetigen’s core competencies in pharmacokinetics with his extensive background in modeling and simulation.
“Dr. Sale is one of the pre-eminent pharmacometricians conducting modeling, simulation, and population PK analyses for pharmaceutical and biotech companies,” said Geoffrey Banks, Ph.D., Kinetigen President and CEO, adding further, “The addition of Dr. Sale as VP of Modeling and Simulation follows our strategic growth initiative to solidify our position as the go-to resource for clinical pharmacology, pharmacokinetics, and model based drug development in the pharmaceutical industry.”
As the former Global Director of Modeling and Simulation for GlaxoSmithKline, Dr. Sale has conducted complex analyses across all nonclinical and clinical phases of drug development and in many therapeutic areas. In addition, he is the developer of parallel NONMEM® and has developed an automated method for population PK model identification. Drawing from his extensive background working with large pharma, Dr. Sale’s renowned simulation and modeling skills provide significant value to Kinetigen’s clientele in terms of improving R&D decision-making ability, supporting drug development strategies, and identifying optimal drug dose(s) for development.
“Kinetigen is positioning itself to be a leader in delivering high quality pharmacokinetic consulting services at a reasonable cost,” said Dr. Sale, adding further, “In addition, their focus on meeting the needs of the client in a timely fashion is key, delivering just what is needed and on time.”
Dr. Sale Received his MD in 1985 from The Ohio State University and an MS in biostatistics from Georgetown University in 1995. Following the completion of a Fellowship in Clinical Pharmacology at Stanford University, he became an Assistant Professor of Medicine and Pharmacology at Georgetown University. In 1998, Dr. Sale joined GlaxoSmithKline and rose to the level of Global Director, Modeling and Simulation prior to starting an independent consultancy in 2006. He currently holds appointments in the Department of Medicine at Indiana University and the Department of Pharmacy at Mercer University.
Dr. Sale joins other industry-leading clinical pharmacology and PK consultants at Kinetigen including Bill Wargin, Ph.D. (CSO) and David Y. Mitchell (VP of PK and Clinical Pharmacology).
Kinetigen, Inc. is a clinical pharmacology consulting firm specializing in pharmacokinetics. Fast becoming the pharmaceutical industry’s go-to resource for pharmacokinetics, Kinetigen gives pharmaceutical companies and CROs rare access to a hands-on team of leading clinical pharmacology and pharmacokinetics professionals experienced in many different therapeutic areas. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic principals and making them understandable and usable for common sense drug development. Kinetigen’s flexible business structure enables us to integrate with our clients and help them maximize the potential of clinical pharmacology studies and pharmacokinetics analyses to pave the way toward marketing approval. For more information visit www.kinetigen.com.